Abstract
Mycoplasma pneumoniae (M. pn) is one of the main pathogens causing community-acquired pneumonia (CAP) in children. In Japan, macrolide (ML)-resistant M. pn was firstly isolated from clinical samples collected from pediatric patients with CAP in 2000, and the agents have rapidly increased. All ML-resistant strains had a point mutation in domain V of the 23S rRNA. Among the patients with ML-resistant M. pn, the duration of fever was significantly longer than in patients with ML-susceptible M. pn infection. The antimicrobial agent was often changed from ML as a first choice agent to minocycline or levofloxacin, because of unimproved clinical symptoms. Further clinical studies are needed to establish appropriate chemotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 251-255 |
| Number of pages | 5 |
| Journal | Nihon rinsho. Japanese journal of clinical medicine |
| Volume | 70 |
| Issue number | 2 |
| Publication status | Published - 2012 Feb 1 |
ASJC Scopus subject areas
- Medicine(all)
Fingerprint Dive into the research topics of '[Macrolide-resistant Mycoplasma pneumoniae].'. Together they form a unique fingerprint.
Cite this
Morozumi, M., & Ubukata, K. (2012). [Macrolide-resistant Mycoplasma pneumoniae]. Nihon rinsho. Japanese journal of clinical medicine, 70(2), 251-255.